Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics

This Viewpoint uses the absence of known effective treatment for Ebola virus disease to emphasize the costs of off-label and compassionate drug use during an infectious disease outbreak and the importance of establishing the efficacy and safety of promising drug leads in randomized trials to inform...

Full description

Saved in:
Bibliographic Details
Published in:JAMA 2020-05, Vol.323 (19), p.1897-1898
Main Author: Kalil, Andre C
Format: Article
Language:English
Subjects:
Clinical trials
COVID-19
Drug use
Infectious diseases
Medical treatment
Pandemics
Randomization
Viral diseases
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This Viewpoint uses the absence of known effective treatment for Ebola virus disease to emphasize the costs of off-label and compassionate drug use during an infectious disease outbreak and the importance of establishing the efficacy and safety of promising drug leads in randomized trials to inform their clinical use.
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2020.4742